{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:09:12Z","timestamp":1787864952486,"version":"build-2784847793"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":307,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010447","name":"German Centre for Cardiovascular Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005971","name":"German Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kroener-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>While it is widely accepted that intravenous (IV) iron improves functional capacity, symptoms, and cardiovascular outcomes in patients with heart failure (HF) with reduced ejection fraction (HFrEF) diagnosed with iron deficiency (ID), three recently published cardiovascular outcome trials (AFFIRM-AHF, IRONMAN and HEART-FID) of IV iron supplementation in HF failed to demonstrate a significant benefit on their respective primary endpoints. Dosing of IV iron after the initial correction of baseline ID \u2013 by design or as a result of trial circumstances \u2013 was relatively low (i.e. &amp;lt;500\u2009mg\/year). The primary objective of the FAIR-HF2 trial is to evaluate the treatment effect of ferric carboxymaltose (FCM) compared with placebo in ambulatory patients with HFrEF using a higher dose of IV iron during follow-up (i.e. &amp;gt;1000\u2009mg\/year). The second objective of the study is to create prospective evidence for patients fulfilling the new definition of ID for patients with HF, i.e. for those with a transferrin saturation\u2009&amp;lt;20%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FAIR-HF2 is an investigator-initiated, multicentre, randomized, double-blind, placebo-controlled trial that has recruited 1105 patients with chronic HF with a left ventricular ejection fraction of \u226445% and concomitant ID, defined as serum ferritin &amp;lt;100\u2009ng\/ml or serum ferritin 100\u2013299\u2009ng\/ml with a transferrin saturation\u2009&amp;lt;20%. Patients were consented and randomized to receive either IV FCM (treatment) or saline (placebo). During an estimated median follow-up of over 2\u2009years, patients underwent a placebo-controlled repletion and maintenance phase, with an initial iron supplementation of up to 2000\u2009mg, followed by 500\u2009mg every 4\u2009months unless stop criteria of haemoglobin &amp;gt;16\u2009mg\/dl or serum ferritin &amp;gt;800\u2009ng\/ml are met on repeat visits. The trial will evaluate three primary hypotheses: (i) time to first event of cardiovascular death or hospitalization for HF, (ii) the rate of total (first and recurrent) HF hospitalizations (both analysed in the full study population), and (iii) the time to first event of cardiovascular death or hospitalization for HF in patients with a transferrin saturation\u2009&amp;lt;20% at baseline. The familywise type I error rate across the three primary endpoint hypotheses will be controlled using the Hochberg procedure (alpha 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The FAIR-HF2 will evaluate the efficacy of FCM in patients with HFrEF in improving cardiovascular outcomes by utilizing a more aggressive approach towards iron supplementation ensuring prevention of transitional ID after initial repletion targets have been met.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3574","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T02:58:32Z","timestamp":1738119512000},"page":"681-689","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Rationale and Design of the FAIR-HF2-DZHK05 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure"],"prefix":"10.1093","volume":"27","author":[{"given":"Stefan D.","family":"Anker","sequence":"first","affiliation":[{"name":"Department of Cardiology (CVK) of German Heart Center Charit\u00e9, Institute of Health Center for Regenerative Therapies (BCRT) , Berlin ,","place":["Germany"]},{"name":"German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Friede","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, University Medical Center G\u00f6ttingen, German Centre for Cardiovascular Research (DZHK), partner site Lower Saxony , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi Medical Center , Jackson, MS ,","place":["USA"]},{"name":"Baylor Scott and White Research Institute , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khawaja M.","family":"Talha","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Loyola University Medical Center , Maywood, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Diek","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK) of German Heart Center Charit\u00e9, Institute of Health Center for Regenerative Therapies (BCRT) , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Nosko","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]},{"name":"German Centre for Cardiovascular Research (DZHK), partner site Hamburg\/Kiel\/L\u00fcbeck , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Placzek","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, University Medical Center G\u00f6ttingen, German Centre for Cardiovascular Research (DZHK), partner site Lower Saxony , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Hasenfu\u00df","sequence":"additional","affiliation":[{"name":"Clinic for Cardiology and Pneumology, University Medical Center G\u00f6ttingen, German Centre for Cardiovascular Research (DZHK), partner site Lower Saxony , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, Wroclaw Medical University , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahir","family":"Karakas","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]},{"name":"German Centre for Cardiovascular Research (DZHK), partner site Hamburg\/Kiel\/L\u00fcbeck , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"2026010913021625900_ejhf3574-bib-0001","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJM199912233412607","article-title":"Disorders of iron metabolism","volume":"341","author":"Andrews","year":"1999","journal-title":"N Engl J Med"},{"key":"2026010913021625900_ejhf3574-bib-0002","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1007\/s00018-009-0051-1","article-title":"Mammalian iron transport","volume":"66","author":"Anderson","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"2026010913021625900_ejhf3574-bib-0003","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and iron deficiency in heart failure","volume":"138","author":"Anand","year":"2018","journal-title":"Circulation"},{"key":"2026010913021625900_ejhf3574-bib-0004","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ejhf.1154","article-title":"Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function","volume":"20","author":"Hoes","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026010913021625900_ejhf3574-bib-0005","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/eurheartj\/ehs377","article-title":"Iron status in patients with chronic heart failure","volume":"34","author":"Jankowska","year":"2013","journal-title":"Eur Heart J"},{"key":"2026010913021625900_ejhf3574-bib-0006","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jchf.2018.07.015","article-title":"Iron deficiency in heart failure: An overview","volume":"7","author":"von Haehling","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026010913021625900_ejhf3574-bib-0007","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"2026010913021625900_ejhf3574-bib-0008","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"2026010913021625900_ejhf3574-bib-0009","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency","volume":"136","author":"van Veldhuisen","year":"2017","journal-title":"Circulation"},{"key":"2026010913021625900_ejhf3574-bib-0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913021625900_ejhf3574-bib-0011","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026010913021625900_ejhf3574-bib-0012","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cardfail.2023.03.025","article-title":"Iron deficiency in heart failure: A scientific statement from the Heart Failure Society of America","volume":"29","author":"Beavers","year":"2023","journal-title":"J Card Fail"},{"key":"2026010913021625900_ejhf3574-bib-0013","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: A multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2026010913021625900_ejhf3574-bib-0014","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): An investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"2026010913021625900_ejhf3574-bib-0015","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"key":"2026010913021625900_ejhf3574-bib-0016","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4081\/cardio.2023.17","article-title":"Defining iron replete status in patients with heart failure treated with intravenous iron","volume":"1","author":"Talha","year":"2023","journal-title":"Global Cardiology"},{"key":"2026010913021625900_ejhf3574-bib-0017","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1093\/eurheartj\/ehad586","article-title":"Efficacy of ferric carboxymaltose in heart failure with iron deficiency: An individual patient data meta-analysis","volume":"44","author":"Ponikowski","year":"2023","journal-title":"Eur Heart J"},{"key":"2026010913021625900_ejhf3574-bib-0018","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ejhf.823","article-title":"Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: An individual patient data meta-analysis","volume":"20","author":"Anker","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026010913021625900_ejhf3574-bib-0019","volume-title":"WMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Subjects \u2013 WMA \u2013 The World Medical Association"},{"key":"2026010913021625900_ejhf3574-bib-0020","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jacc.2023.07.024","article-title":"Recurrent events in cardiovascular trials: JACC state-of-the-art review","volume":"82","author":"Gregson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026010913021625900_ejhf3574-bib-0021","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jamacardio.2019.3080","article-title":"Occurence of first and recurrent major adverse cardiovascular events with liraglutide treatment among patients with type 2 diabetes and high risk of cardiovascular events: A post hoc analysis of a randomized clinical trial","volume":"4","author":"Verma","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026010913021625900_ejhf3574-bib-0022","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa2314328","article-title":"Transcatheter valve repair in heart failure with moderate to severe mitral regurgitation","volume":"391","author":"Anker","year":"2024","journal-title":"N Engl J Med"},{"key":"2026010913021625900_ejhf3574-bib-0023","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010913021625900_ejhf3574-bib-0024","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jacc.2021.11.039","article-title":"Criteria for iron deficiency in patients with heart failure","volume":"79","author":"Masini","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026010913021625900_ejhf3574-bib-0025","article-title":"Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients","volume":"11","author":"Beverborg","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026010913021625900_ejhf3574-bib-0026","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/eurheartj\/ehae086","article-title":"Intravenous iron for heart failure, iron deficiency definitions, and clinical response: The IRONMAN trial","volume":"45","author":"Cleland","year":"2024","journal-title":"Eur Heart J"},{"key":"2026010913021625900_ejhf3574-bib-0027","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4081\/cardio.2024.33","article-title":"Using multiple primary endpoints in clinical trials with a focus on heart failure","volume":"2","author":"Anker","year":"2024","journal-title":"Global Cardiology"},{"key":"2026010913021625900_ejhf3574-bib-0028","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ahj.2007.03.025","article-title":"Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: Data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial","volume":"154","author":"Dobre","year":"2007","journal-title":"Am Heart J"},{"key":"2026010913021625900_ejhf3574-bib-0029","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 Focused Update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026010913021625900_ejhf3574-bib-0030","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"2026010913021625900_ejhf3574-bib-0031","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"key":"2026010913021625900_ejhf3574-bib-0032","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jacc.2017.12.048","article-title":"2017 Cardiovascular and stroke endpoint definitions for clinical trials","volume":"71","author":"Hicks","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026010913021625900_ejhf3574-bib-0033","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/ejhf.2816","article-title":"Dosing of iron supplementation for iron-deficient patients with heart failure: Should we prefer more intensive or less intensive repletion targets?","volume":"25","author":"Packer","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026010913021625900_ejhf3574-bib-0034","first-page":"2109","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Anker","year":"2023","journal-title":"N Engl J Med"},{"key":"2026010913021625900_ejhf3574-bib-0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4081\/cardio.2023.2","article-title":"SGLT2 inhibitors and risk reduction for mortality in high-risk patients: A meta-analysis of randomized controlled trials","volume":"1","author":"Siddiqi","year":"2023","journal-title":"Global Cardiology"},{"key":"2026010913021625900_ejhf3574-bib-0036","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.0000000000000362","article-title":"Alleviation of anemia by SGLT2 inhibitors in patients with CKD","volume":"19","author":"Packer","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026010913021625900_ejhf3574-bib-0037","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/ehf2.14742","article-title":"Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction","volume":"11","author":"Docherty","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026010913021625900_ejhf3574-bib-0038","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jchf.2022.10.004","article-title":"Potential interactions when prescribing SGLT2 inhibitors and intravenous iron in combination in heart failure","volume":"11","author":"Packer","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026010913021625900_ejhf3574-bib-0039","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/CIRCULATIONAHA.122.060511","article-title":"Iron deficiency in heart failure and effect of dapagliflozin: Findings from DAPA-HF","volume":"146","author":"Docherty","year":"2022","journal-title":"Circulation"},{"key":"2026010913021625900_ejhf3574-bib-0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4081\/cardio.2023.6","article-title":"Evolving targets for heart failure: The journey so far","volume":"1","author":"Rosano","year":"2023","journal-title":"Global Cardiology"},{"key":"2026010913021625900_ejhf3574-bib-0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4081\/cardio.2023.1","article-title":"Welcome to global cardiology","volume":"1","author":"Coats","year":"2023","journal-title":"Global Cardiology"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/4\/681\/65242913\/eurjhf_27_4_681.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/4\/681\/65242913\/eurjhf_27_4_681.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:02:30Z","timestamp":1767981750000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/4\/681\/8316342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,1,28]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3574","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"2024-10-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}